Format

Send to

Choose Destination
Vaccine. 2017 Feb 7;35(6):853-855. doi: 10.1016/j.vaccine.2017.01.009. Epub 2017 Jan 13.

Re-assessing the total burden of norovirus circulating in the United Kingdom population.

Author information

1
National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at the University of Liverpool, Liverpool, UK. Electronic address: john.harris@liverpool.ac.uk.
2
National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at the University of Liverpool, Liverpool, UK.

Abstract

The second Infectious Intestinal Diseases study (IID2) estimated the incidence of norovirus in the UK at 47/1000 population (three million cases annually). Clinically significant norovirus was defined using a cycle threshold (ct) value of <30; a more stringent cut-off than used in diagnostic laboratories. The low infectious dose of norovirus means asymptomatic individuals potentially contribute to ongoing transmission. Using a less stringent but diagnostically relevant threshold increases the estimation of the population burden of norovirus infection by around 26% to 59/1000 person years (95% CI 52.32-64.98), equating to 3.7 million norovirus infections annually (3.3-4.1 million). With possible vaccines on the horizon for norovirus, having a good estimate of the total burden of norovirus infection, as well as symptomatic disease will be useful in helping to guide vaccination policy when candidate vaccines become available.

KEYWORDS:

Calicivirus; Gastrointestinal infections; Infectious diseases; Norovirus

PMID:
28094075
PMCID:
PMC5287221
DOI:
10.1016/j.vaccine.2017.01.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center